8 completed, 7 active not recruiting, 5 recruiting, 1 not yet recruiting. 10 Phase 1, 7 Phase 2, 6 Phase 3.
By phase and status
Follow AZD9833: new trials by email Literature Review of AZD9833 trials Research Report on AZD9833
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Phase II Study of CAmizestrant in Resectable Endometrial Adenocarcinoma Camizestrant - Estrogen Receptor-positive, Early Stage Endometrial Cancer Phase 2 Not yet recruiting University Health Network, Toronto 30 2026-10-26 2026-09-25 A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer Camizestrant, Ribociclib - ER-Positive HER2-Negative Breast Cancer Phase 3 Recruiting AstraZeneca 150 2026-06-15 2026-10-19 Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer Camizestrant, Atirmociclib - Advanced Breast Cancer Phase 2 Recruiting AstraZeneca 24 2026-05-06 2026-09-29 Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer Camizestrant, Ribociclib - Hormon Receptor Positive Breast Cancer, Breast Cancer Phase 2 Recruiting MedSIR 150 2026-03-24 2026-05-29 A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants Midazolam, Camizestrant, Carbamazepine - Healthy Participants Phase 1 Completed AstraZeneca 40 2024-08-27 2025-09-04 Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer Saruparib (AZD5305), Camizestrant, Abemaciclib - Advanced Breast Cancer Phase 3 Recruiting AstraZeneca 788 2024-08-01 2026-09-02 A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors AZD8421, Camizestrant, Ribociclib - ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC) Phase 1 / Phase 2 Active not recruiting AstraZeneca 55 2023-12-05 2026-10-23 An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Camizestrant, Tamoxifen, Anastrozole - Breast Cancer, Early Breast Cancer Phase 3 Active not recruiting AstraZeneca 5511 2023-10-05 2026-08-10 A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy Camizestrant, Tamoxifen, Anastrozole - Breast Cancer, Early Breast Cancer Phase 3 Recruiting AstraZeneca 4300 2023-03-31 2026-10-13 Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects Camizestrant - Hepatic Impairment Phase 1 Completed AstraZeneca 22 2023-02-20 2025-03-25 A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole Camizestrant, Itraconazole - Healthy Subjects Phase 1 Completed AstraZeneca 14 2022-10-04 2023-01-06 Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers AZD9833, Midazolam, Omeprazole - Healthy Volunteers Phase 1 Completed AstraZeneca 59 2022-06-13 2023-01-12 AZD9833 China PK Study AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus - ER+, HER2-, Metastatic Breast Cancer Phase 1 Completed AstraZeneca 28 2021-11-12 2024-12-17 Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) AZD9833, AZD9833 Placebo, Anastrozole - ER-Positive HER2-Negative Breast Cancer Phase 3 Active not recruiting AstraZeneca 315 2021-06-30 2026-09-23 A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease AZD9833, Anastrozole, Anastrozole placebo - ER-Positive HER2-Negative Breast Cancer Phase 3 Active not recruiting AstraZeneca 1371 2021-01-28 2026-09-28 Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies AZD5305, Paclitaxel, Carboplatin - Ovarian Cancer, Breast Cancer Phase 1 / Phase 2 Active not recruiting AstraZeneca 702 2020-11-12 2026-09-21 A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer AZD9833 - HER2-negative Breast Cancer Phase 2 Completed AstraZeneca 135 2020-11-02 2025-01-24 A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer AZD9833 - ER+ HER2- Advanced Breast Cancer Phase 1 Completed AstraZeneca 10 2020-09-29 2025-08-07 A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833 [14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL), AZD9833 film-coated tablet A Dose 1, AZD9833 Oral Solution - Healthy Volunteers Phase 1 Completed AstraZeneca 32 2020-09-17 2021-01-20 A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer AZD9833, Fulvestrant - Advanced ER-Positive HER2-Negative Breast Cancer Phase 2 Active not recruiting AstraZeneca 240 2020-04-22 2026-08-26
Showing 20 of 21. Sign in to see all of them.
Conditions studied Breast Neoplasms (15) · Neoplasm Metastasis (4) · Breast Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Biliary Tract Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Lymphoma, Follicular (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Skin Diseases (1) · Stomach Neoplasms (1)
Sponsors AstraZeneca (19) · MedSIR (1) · University Health Network, Toronto (1)
Countries United Kingdom (14) · United States (13) · Spain (11) · South Korea (9) · Canada (8) · Germany (8) · Italy (8) · Poland (8) · France (7) · Hungary (7) · Japan (7) · Australia (6) · Bulgaria (6) · China (6) · Portugal (6)
Top investigators Jian Zhang (1) · Jiong Wu (1) · John Robertson (1) · Justin Lindemann, MBChB MBA (1) · Richard Baird, MD PhD FRCP (1) · Richard Baird, MD, PhD (1) · Somasekhara Menakuru, MBBS MS MRCS (1) · Stephanie Lheureux, MD, PhD (1) · Timothy Yap (1)
Results publications PMID 38729567 , PMID 40017004 , PMID 35929986 , PMID 37070653 , PMID 39481395 , PMID 40454637 , PMID 41628308 , PMID 42442380 , PMID 42496653
NIH funding 2023 (5), 2018 (1), 2019 (1)